SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Lepu Biopharma’s CMG901 Improves Overall Survival in Phase III Trial

Lepu Biopharma said CMG901 improved overall survival in a Phase III gastroesophageal cancer trial.

Related stories